Clinical trials for Targeted Radiotherapy and Imaging in pediatric cancers are derived from the translational work of our CENTRIC program team and other research labs at the University of Wisconsin-Madison. This program is one of a handful of programs that offer 131I-MIBG radionuclide therapy for neuroblastoma, pheochromocytoma and paraganglioma. The program is also one of only five centers able to administer a new radiopharmaceutical, CLR131 (an alkyl phospholipid ether analog targeting a wide range of pediatric cancers). TRIPP is the only center in the U.S to open the “MiNivAn” trial which combines 131I-MIBG with immunotherapy. The focus of CENTRIC is to provide radionuclide therapies and MIBG or related therapies in the state of Wisconsin and surrounding areas.
Therapies offered currently:
https://clinicaltrials.gov/ct2/results?cond=&term=targeted+radiotherapy+OR+radionuclide+OR+radiopharmaceuticals&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=Wisconsin%2C+Madison&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=
What patients can expect:
https://www.uwhealth.org/video/mibg-therapy-at-american-family-childrens-hospital/29647
UW Clinical Trials Office
https://ictr.wisc.edu/about-ictr/
Email: info@ictr.wisc.edu
Phone: (608) 263-1018